Amonafide (originally AS1413) (
INN
Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...
, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of
cancer
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...
. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential
topoisomerase inhibitor and
DNA intercalator.
It was being developed as an anti-cancer therapy by
Antisoma.
, it is in
Phase III clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietar ...
s.
e.g. In March 2010 it is
Phase III trial against secondary
acute myeloid leukaemia
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include ...
(AML).
In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.
See also
*
Alrestatin
Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
Alrestat was first synthesized in 1969 and was the first aldose reductase inhibitor (ARI) ...
References
External links
Amonafideentry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafideat ClinicalTrials.gov
Experimental cancer drugs
{{antineoplastic-drug-stub